Gwenn Hansen Sells 4,895 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 4,895 shares of the company’s stock in a transaction on Friday, January 30th. The stock was sold at an average price of $16.60, for a total value of $81,257.00. Following the transaction, the insider directly owned 83,672 shares in the company, valued at approximately $1,388,955.20. This represents a 5.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Nurix Therapeutics Stock Performance

NASDAQ NRIX opened at $16.52 on Friday. The stock has a market capitalization of $1.27 billion, a P/E ratio of -5.43 and a beta of 1.93. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $22.50. The stock has a fifty day moving average of $18.50 and a 200-day moving average of $13.37.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Wednesday, January 28th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.02. The business had revenue of $13.58 million for the quarter, compared to analysts’ expectations of $13.41 million. Nurix Therapeutics had a negative return on equity of 57.51% and a negative net margin of 314.90%. Equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Nurix Therapeutics News Roundup

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada raised its price target on NRIX to $30 and maintained an outperform view, signaling significant upside versus the current stock level. RBC increases price target to $30
• Positive Sentiment: Needham & Company reaffirmed a “buy” rating with a $26 target and BTIG reiterated a buy with a $30 target — multiple brokerages maintaining bullish outlooks provide support for upside expectations. Needham and BTIG ratings
• Negative Sentiment: Insiders sold shares on Jan. 30: Gwenn Hansen sold 4,895 shares at ~$16.60 and CFO Houte Hans Van sold 3,661 shares at ~$16.60. Insider sales can be viewed negatively by the market because they reduce insider ownership and may signal cashing out. SEC filings: Hansen Form 4 and Van Form 4
• Negative Sentiment: TipRanks highlighted a newly disclosed material foreign‑exchange risk for Nurix due to unhedged currency exposure, which could increase earnings volatility and raise capital‑markets uncertainty. TipRanks: FX risk disclosed

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Royal Bank Of Canada increased their price objective on shares of Nurix Therapeutics from $28.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday. Stifel Nicolaus increased their price target on Nurix Therapeutics from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday. Oppenheimer reduced their price target on Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating on the stock in a research report on Friday, October 10th. Morgan Stanley set a $36.00 price objective on Nurix Therapeutics and gave the company an “overweight” rating in a report on Thursday, January 8th. Finally, Piper Sandler increased their target price on Nurix Therapeutics from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NRIX. Pictet Asset Management Holding SA grew its stake in Nurix Therapeutics by 75.1% in the fourth quarter. Pictet Asset Management Holding SA now owns 3,467,600 shares of the company’s stock valued at $65,780,000 after acquiring an additional 1,487,060 shares during the period. UBS Group AG lifted its holdings in shares of Nurix Therapeutics by 16.8% during the 4th quarter. UBS Group AG now owns 423,425 shares of the company’s stock valued at $8,032,000 after purchasing an additional 60,879 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Nurix Therapeutics by 32.5% in the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock valued at $112,862,000 after purchasing an additional 1,460,736 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Nurix Therapeutics by 23.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,518 shares of the company’s stock worth $313,000 after purchasing an additional 3,118 shares in the last quarter. Finally, Arizona State Retirement System increased its stake in Nurix Therapeutics by 8.2% during the 4th quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock worth $417,000 after purchasing an additional 1,674 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.